相关实验视频

Updated: Jul 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

化疗诱导的中性作为晚期上皮质卵巢癌患者的预后因素

Yaping Xu^1,2, Mingjing Wei¹, Xiaodong Cheng^1,3,4

¹Department of Gynecologic Oncology, Women's Hospital School of Medicine Zhejiang University, Hangzhou, China.

Cancer control : journal of the Moffitt Cancer Center

|July 3, 2023

概括

化疗诱导的中性质减退 (CIN) 可能预测晚期上皮卵巢癌 (EOC) 患者的生存率更好,特别是那些接受低于最佳的手术的患者. 这一发现为EOC治疗结果提供了潜在的预后指标.

科学领域:

在瘤学瘤学.
妇科瘤学妇科瘤学
临床药理学临床药理学

背景情况:

卵巢上皮癌 (EOC) 是女性癌症相关死亡的一个重要原因.
基于的化疗是初级手术后EOC的基石治疗.
化疗诱导的中性质减退 (CIN) 是一种常见的副作用,可能会影响治疗疗效和患者的治疗结果.

研究的目的:

在上皮卵巢癌 (EOC) 患者中研究化疗诱导的中性质衰竭 (CIN) 的预后价值.
确定CIN是否可以作为EOC的总生存率 (OS) 和无进展生存率 (PFS) 的独立预测指标.
探索CIN与高级EOC的生存结果之间的关联,特别是在次优化手术后.

主要方法:

在2002年至2016年期间接受治疗的735名初级EOC患者的回顾性审查.
化学治疗后CIN定义为绝对中性粒细胞数 (ANC) <2.0 × 10^9/L;进一步分为轻度/重度和早期/晚期发病.
统计分析包括奇平方测试,卡普兰-梅尔分析和OS和PFS的单变量/多变量考克斯回归模型.

主要成果:

没有观察到有或没有CIN的患者之间或基于CIN严重程度或时间的预后差异.
然而,CIN与晚期EOC患者的更好的整体存活率 (OS) 有显著的关联 (P=0.004).
亚组分析显示,CIN是更好的PFS (P=0.019) 和OS (P=0.048) 的独立预测因子,特别是在接受了次优化手术的高级EOC患者中.

结论:

化疗诱导的中性质减退 (CIN) 可能作为高级上皮卵巢癌 (EOC) 的有价值的独立预后指标.
CIN的预后意义在经过低于最佳的外科治疗的晚期EOC患者中尤为明显.
需要进一步的研究,以阐明CIN与特定EOC患者子组中改善生存率之间的关联背后的机制.

关键词:

癌症的生存率癌症的生存率化学疗法诱导的中性质衰竭.卵巢上皮癌卵巢上皮癌基于的化学疗法.预后因素是一个预后因素.

更多相关视频

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...